222 related articles for article (PubMed ID: 36876333)
1. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials.
Neurath L; D'Amico F; Danese S
Expert Opin Emerg Drugs; 2023 Mar; 28(1):27-42. PubMed ID: 36876333
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies for ulcerative colitis.
Hanzel J; Hulshoff MS; Grootjans J; D'Haens G
Expert Rev Clin Immunol; 2022 May; 18(5):513-524. PubMed ID: 35477319
[TBL] [Abstract][Full Text] [Related]
4. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis.
Law CCY; Kayal M; Mehandru S; Colombel JF
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073
[TBL] [Abstract][Full Text] [Related]
5. Filgotinib for moderately to severely active ulcerative colitis.
Mannucci A; D'Amico F; El Saadi A; Peyrin-Biroulet L; Danese S
Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):927-940. PubMed ID: 36278878
[TBL] [Abstract][Full Text] [Related]
6. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
7. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
Nakase H
Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
[TBL] [Abstract][Full Text] [Related]
8. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
[TBL] [Abstract][Full Text] [Related]
9. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
10. Review article: novel oral-targeted therapies in inflammatory bowel disease.
White JR; Phillips F; Monaghan T; Fateen W; Samuel S; Ghosh S; Moran GW
Aliment Pharmacol Ther; 2018 Jun; 47(12):1610-1622. PubMed ID: 29672874
[TBL] [Abstract][Full Text] [Related]
11. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
12. Ozanimod: A Review in Ulcerative Colitis.
Paik J
Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
14. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.
Napolitano M; D'Amico F; Ragaini E; Peyrin-Biroulet L; Danese S
Drug Des Devel Ther; 2022; 16():1897-1913. PubMed ID: 35747444
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond.
Neri B; Mancone R; Fiorillo M; Schiavone SC; De Cristofaro E; Migliozzi S; Biancone L
Expert Opin Pharmacother; 2024 Apr; 25(5):485-499. PubMed ID: 38591242
[TBL] [Abstract][Full Text] [Related]
17. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Emerg Drugs; 2022 Dec; 27(4):369-377. PubMed ID: 36369862
[TBL] [Abstract][Full Text] [Related]
20. Novel and emerging drugs for the treatment of Crohn's disease: a review of phase II and III trials.
Wetwittayakhlang P; Bessissow T; Lakatos PL
Expert Opin Emerg Drugs; 2024 Mar; 29(1):19-34. PubMed ID: 38193191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
